A few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new valsartan offering to help relieve shortages flowing from massive recalls of tainted versions of generic Diovan.
